Possible involvement of transglutaminase-catalyzed reactions in the physiopathology of neurodegenerative diseases

Amino Acids

Volumn 44, Issue 1, 2013, Pages 111-118

  Martin, Antonio ^a   Giuliano, Alessandro ^a   Collaro, Domenico ^a   De Vivo, Giulia ^a   Sedia, Carla ^a   Serretiello, Enrica ^a   Gentile, Vittorio ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Nervous System; Neurodegenerative diseases; Post translational modifications of proteins; Transglutaminases

Indexed keywords

CYSTAMINE; POLYGLUTAMINE; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2;

ALZHEIMER DISEASE; CATALYSIS; DEGENERATIVE DISEASE; DENTATORUBROPALLIDOLUYSIAN ATROPHY; DISEASE COURSE; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; HUNTINGTON CHOREA; NONHUMAN; OCULOPHARYNGEAL MUSCULAR DYSTROPHY; PARKINSON DISEASE; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; REVIEW;

ANIMALS; CELL DEATH; GLUTAMINE; HUMANS; LYSINE; MOLECULAR TARGETED THERAPY; NEURODEGENERATIVE DISEASES; PEPTIDES; PROTEIN PROCESSING, POST-TRANSLATIONAL; TRANSGLUTAMINASES;

EID: 84871960070     PISSN: 09394451     EISSN: 14382199     Source Type: Journal    
DOI: 10.1007/s00726-011-1081-1     Document Type: Review

References (50)

1. Achyuthan KE, Greenberg CS (1987) Identification of a guanosine triphosphate-binding site on guinea pig liver transglutaminase. Role of GTP and calcium ions in modulating activity. J Biol Chem 262:1901-1906
2. Adams RD, Victor M (1993) Principles of neurology. McGraw-Hill, Inc. New York
3. Appelt DM, Kopen GC, Boyne LJ, Balin BJ (1996) Localization of transglutaminase in hippocampal neurons: implications for Alzheimer's disease. J Histochem Cytochem 44:1421-1427
4. Citron BA, Santa Cruz KS, Davies PJ, Festoff BW (2001) Intron-exon swapping of transglutaminase mRNA and neuronal tau aggregation in Alzheimer's disease. J Biol Chem 276:3295-3301
5. Citron BA, Suo Z, SantaCruz K, Davies PJ, Qin F, Festoff BW (2002) Protein crosslinking, tissue transglutaminase, alternative splicing and neurodegeneration. Neurochem Int 40:69-78
6. Davies JE, Rose C, Sarkar S, Rubinsztein DC (2010) Cystamine suppresses polyalanine toxicity in a mouse model of oculopharyngeal muscular dystrophy. Sci Transl Med 2:34ra40
7. De Laurenzi V, Melino G (2001) Gene disruption of tissue transglutaminase. Mol Cell Biol 21:148-155
8. Dedeoglu A, Kubilus JK, Jeitner TM, Matson SA, Bogdanov M, Kowall NW, Matson WR, Cooper AJ, Ratan RR, Beal MF, Hersch SM, Ferrante RJ (2002) Therapeutic effects of cystamine in a murine model of Huntington's disease. J Neurosci 22:8942-8950
9. Dudek SM, Johnson GV (1993) Transglutaminase catalyzes the formation of sodium dodecyl sulfate-insoluble, Alz-50-reactive polymers of tau. J Neurochem 61:1159-1162
10. Dudek SM, Johnson GV (1994) Transglutaminase facilitates the formation of polymers of the beta-amyloid peptide. Brain Res 651:129-133
11. Fleckenstein B, Qiao SW, Larsen MR, Jung G, Roepstorff P, Sollid LM (2004) Molecular characterization of covalent complexes between tissue transglutaminase and gliadin peptides. J Biol Chem 279:17607-17616
12. Folk JE (1983) Mechanism and basis for specificity of transglutaminase-catalyzed ε-(γ-glutamyl)lysine bond formation. Adv Enzymol Relat Areas Mol Biol 54:1-56
13. Gentile V, Porta R, Chiosi E, Spina A, Caputo I, Valente F, Pezone R, Davies PJA, Illiano G (1997) Tissue transglutaminase and adenylate cyclase interactions in Balb-C 3T3 fibroblast membranes. Biochim Biophys Acta 1357:115-122
14. Gentile V, Sepe C, Calvani M, Melone MAB, Cotrufo R, Cooper AJL, Blass JP, Peluso G (1998) Tissue transglutaminase-catalyzed formation of high-molecular-weight aggregates in vitro is favored with long polyglutamine domains: a possible mechanism contributing to CAG-triplet diseases. Arch Biochem Biophys 352:314-321
15. Grierson AJ, Johnson GV, Miller CC (2001) Three different human τ isoforms and rat neurofilament light, middle and heavy chain proteins are cellular substrates for transglutaminase. Neurosci Lett 298:9-12
16. Griffith OW, Larsson A, Meister A (1997) Inhibition of γ-glutamylcysteine synthetase by cystamine: an approach to a therapy of 5-oxoprolinuria (pyroglutamic aciduria). Biochem Biophys Res Commun 79:919-925
17. Hadjivassiliou M, Aeschlimann P, Strigun A, Sanders DS, Woodroofe N, Aeschlimann D (2008) Autoantibodies in gluten ataxia recognize a novel neuronal transglutaminase. Ann Neurol 64:332-343
18. Hartley DM, Zhao C, Speier AC, Woodard GA, Li S, Li Z, Walz T (2008) Transglutaminase induces protofibril-like amyloid β-protein assemblies that are protease-resistant and inhibit long-term potentiation. J Biol Chem 283:16790-16800
19. Hasegawa G, Suwa M, Ichikawa Y, Ohtsuka T, Kumagai S, Kikuchi M, Sato Y, Saito Y (2003) A novel function of tissue-type transglutaminase: protein disulfide isomerase. Biochem J 373:793-803
20. Igarashi S, Koide R, Shimohata T, Yamada M, Hayashi Y, Takano H, Date H, Oyake M, Sato A, Egawa S, Ikeuchi T, Tanaka H, Nakano R, Tanaka K, Hozumi I, Inuzuka T, Takahashi H, Tsuji S (1998) Suppression of aggregate formation and apoptosis by transglutaminase inhibitors in cells expressing truncated DRPLA protein with an expanded polyglutamine stretch. Nat Genet 18:111-117
21. Iuchi S, Hoffner G, Verbeke P, Djian P, Green H (2003) Oligomeric and polymeric aggregates formed by proteins containing expanded polyglutamine. Proc Natl Acad Sci USA 100:2409-2414
22. Jeitner TM, Matson WR, Folk JE, Blass JP, Cooper AJL (2008) Increased levels of γ-glutamylamines in Huntington disease CSF. J Neurochem 106:37-44
23. Junn E, Ronchetti RD, Quezado MM, Kim SY, Mouradian MM (2003) Tissue transglutaminase-induced aggregation of α-synuclein: Implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci USA 100:2047-2052
24. Kahlem P, Green H, Djian P (1998) Transglutaminase action imitates Huntington's disease: selective polymerization of huntingtin containing expanded polyglutamine. Mol Cell 1:595-601
25. Karpuj MV, Becher MW, Springer JE, Chabas D, Youssef S, Pedotti R, Mitchell D, Steinman L (2002) Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine. Nat Med 8:143-149
26. Karpuj MV, Garren H, Slunt H, Price DL, Gusella J, Becher MW, Steinman L (1999) Transglutaminase aggregates huntingtin into nonamyloidogenic polymers, and its enzymatic activity increases in Huntington's disease brain nuclei. Proc Natl Acad Sci USA 96:7388-7393
27. Kim CY, Quarsten H, Bergseng E, Khosla C, Sollid LM (2004) Structural basis for HLA-DQ2-mediated presentation of gluten epitopes in celiac disease. Proc Natl Acad Sci USA 101:4175-4179
28. Kim S-Y, Grant P, Lee JHC, Pant HC, Steinert PM (1999) Differential expression of multiple transglutaminases in human brain. Increased expression and cross-linking by transglutaminase 1 and 2 in Alzheimer's disease. J Biol Chem 274:30715-30721
29. Krasnikov BF, Kim SY, McConoughey SJ, Ryu H, Xu H, Stavrovskaya I, Iismaa SE, Mearns BM, Ratan RR, Blass JP, Gibson GE, Cooper AJ (2005) Transglutaminase activity is present in highly purified nonsynaptosomal mouse brain and liver mitochondria. Biochemistry 44:7830-7843
30. Lahav J, Karniel E, Bagoly Z, Sheptovitsky V, Dardik R, Inbal A (2009) Coagulation factor XIII serves as protein disulfide isomerase. Thromb Haemost 101:840-844
31. Lai T-S, Liu Y, Weidong L, Greenberg C (2007) Identification of two GTP independent alternatively spliced forms of tissue transglutaminase in human leukocytes, vascular smooth muscle, and endothelial cells. FASEB J 21:4131-4134
32. Lesort M, Lee M, Tucholski J, Johnson GVW (2003) Cystamine inhibits caspase activity. Implications for the treatment of polyglutamine disorders. J Biol Chem 278:3825-3830
33. Lorand L, Graham RM (2003) Transglutaminases: crosslinking enzymes with pleiotropic functions. Nat Mol Cell Biol 4:140-156
34. Mastroberardino PG, Iannicola C, Nardacci R, Bernassola F, De Laurenzi V, Melino G, Moreno S, Pavone F, Oliviero S, Fesus L, Piacentini M (2002) 'Tissue' transglutaminase ablation reduces neuronal death and prolongs survival in a mouse model of Huntington's disease. Cell Death Differ 9:873-880
35. McConoughey SJ, Basso M, Niatsetskaya ZV, Sleiman SF, Smirnova NA, Langley BC, Mahishi L, Cooper AJ, Antonyak MA, Cerione RA, Li B, Starkov A, Chaturvedi RK, Beal MF, Coppola G, Geschwind DH, Ryu H, Xia L, Iismaa SE, Pallos J, Pasternack R, Hils M, Fan J, Raymond LA, Marsh JL, Thompson LM, Ratan RR (2010) Inhibition of transglutaminase 2 mitigates transcriptional dysregulation in models of Huntington disease. EMBO Mol Med 2:349-370
36. Mian S, El Alaoui S, Lawry J, Gentile V, Davies PJA, Griffin M (1995) The importance of the GTP binding protein tissue transglutaminase in the regulation of cell cycle progression. FEBS Lett 370:27-31
37. Miller ML, Johnson GV (1995) Transglutaminase cross-linking of the tau protein. J Neurochem 65:1760-1770
38. Monsonego A, Shani Y, Friedmann I, Paas Y, Eizenberg O, Schwartz M (1997) Expression of GTP-dependent and GTP-independent tissue-type transglutaminase in cytokine-treated rat brain astrocytes. J Biol Chem 272:3724-3732
39. Nakaoka H, Perez DM, Baek KJ, Das T, Husain A, Misono K, Im MJ, Graham RM (1994) Gh: a GTP-binding protein with transglutaminase activity and receptor signalling function. Science 264:1593-1596
40. Nanda N, Iismaa SE, Owens WA, Husain A, Mackay F, Graham RM (2001) Targeted inactivation of Gh/tissue transglutaminase II. J Biol Chem 276:20673-20678
41. Piacentini M, Martinet N, Beninati S, Folk JE (1988) Free and protein conjugated-polyamines in mouse epidermal cells. Effect of high calcium and retinoic acid. J Biol Chem 263:3790-3794
42. Schmid AW, Condemi E, Tuchscherer G, Chiappe D, Mutter M, Vogel H, Moniatte M, Tsybin YO (2011) Tissue transglutaminase-mediated glutamine deamidation of β-amyloid peptide increases peptide solubility, whereas enzymatic cross-linking and peptide fragmentation may serve as molecular triggers for rapid peptide aggregation. J Biol Chem 286:12172-12188
43. Selkoe DJ, Abraham C, Ihara Y (1982) Alzheimer's disease: insolubility of partially purified paired helical filaments in sodium dodecyl sulfate and urea. Proc Natl Acad Sci USA 79:6070-6074
44. Singer SM, Zainelli GM, Norlund MA, Lee JM, Muma NA (2002) Transglutaminase bonds in neurofibrillary tangles and paired helical filament tau early in Alzheimer's disease. Neurochem Int 40:17-30
45. Smethurst PA, Griffin M (1996) Measurement of tissue transglutaminase activity in a permeabilized cell system: its regulation by calcium and nucleotides. Biochem J 313:803-808
46. Tee AEL, Marshall GM, Liu PY, Xu N, Haber M, Norris MD, Iismaa SE, Liu T (2010) Opposing effects of two tissue transglutaminase protein isoforms in neuroblastoma cell differentiation. J Biol Chem 285:3561-3567
47. Thomazy V, Fesus L (1989) Differential distribution of tissue transglutaminase in human cells: An immunohistochemical study. Cell Tissue Res 255:215-224
48. Verhoef LGGC, Lindsten K, Masucci MG, Dantuma NP (2002) Aggregate formation inhibits proteasomal degradation of polyglutamine proteins. Hum Mol Genet 11:2689-2700
49. Wilhelmus MM, Grunberg SC, Bol JG, van Dam AM, Hoozemans JJ, Rozenmuller AJ, Drukarch B (2009) Transglutaminases and transglutaminase-catalyzed cross-links colocalize with the pathological lesions in Alzheimer's disease brain. Brain Pathol 19:612-622
50. Zemaitaitis MO, Kim SY, Halverson RA, Troncoso JC, Lee JM, Muma NA (2003) Transglutaminase activity, protein, and mRNA expression are increased in progressive supranuclear palsy. J Neuropathol Exp Neurol 62:173-184